273 related articles for article (PubMed ID: 31622558)
1. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers.
Schroader B; Kong S; Anderson S; Williamson T; Sireci A; Shields K
Expert Rev Anticancer Ther; 2019 Nov; 19(11):929-938. PubMed ID: 31622558
[No Abstract] [Full Text] [Related]
2. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.
Mohindra N; Agulnik M
Expert Opin Investig Drugs; 2015; 24(11):1409-18. PubMed ID: 26289790
[TBL] [Abstract][Full Text] [Related]
4. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
5. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
6. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
8. TRK inhibition in soft tissue sarcomas: A comprehensive review.
Assi T; Rassy E; Nassereddine H; Farhat F; Karak FE; Kattan J; Ghosn M
Semin Oncol; 2020 Feb; 47(1):73-84. PubMed ID: 32201016
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries.
Cardona AF; Arrieta O; Ruiz-Patiño A; Sotelo C; Zamudio-Molano N; Zatarain-Barrón ZL; Ricaurte L; Raez L; Álvarez MPP; Barrón F; Rojas L; Rolfo C; Karachaliou N; Molina-Vila MA; Rosell R
Ther Adv Respir Dis; 2020; 14():1753466620938553. PubMed ID: 32643553
[TBL] [Abstract][Full Text] [Related]
10. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
11. Newer medical therapies for metastatic soft tissue sarcoma.
Tiwari A; Gupta VG; Bakhshi S
Expert Rev Anticancer Ther; 2017 Mar; 17(3):257-270. PubMed ID: 28103739
[TBL] [Abstract][Full Text] [Related]
12. Impact of tissue-agnostic approvals for patients with sarcoma.
Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
[TBL] [Abstract][Full Text] [Related]
13. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
14. Histology-agnostic drug development - considering issues beyond the tissue.
Pestana RC; Sen S; Hobbs BP; Hong DS
Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
[TBL] [Abstract][Full Text] [Related]
15. A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.
Alavi SN; Florou V; Tinoco G; Trent JC; Wilky BA
Discov Med; 2018 Mar; 25(137):131-144. PubMed ID: 29641974
[TBL] [Abstract][Full Text] [Related]
16. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database.
Pestana RC; Serrano C
Front Oncol; 2022; 12():1079909. PubMed ID: 36741731
[TBL] [Abstract][Full Text] [Related]
17. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
18. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality.
Tarantino P; Mazzarella L; Marra A; Trapani D; Curigliano G
Cancer Treat Rev; 2021 Mar; 94():102169. PubMed ID: 33652262
[TBL] [Abstract][Full Text] [Related]
19. Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.
Badalamenti G; Messina C; De Luca I; Musso E; Casarin A; Incorvaia L
Radiol Med; 2019 Apr; 124(4):259-265. PubMed ID: 29619613
[TBL] [Abstract][Full Text] [Related]
20. Addressing Modern Diagnostic Pathology for Patient-Derived Soft Tissue Sarcosphere Models in the Era of Functional Precision Oncology.
Chen Y; Herzog M; Pliego-Mendieta A; Bühler MM; Harnisch KJ; Haberecker M; Arnold F; Planas-Paz L; Pauli C
Lab Invest; 2023 Apr; 103(4):100039. PubMed ID: 36870294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
